In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaxart, Inc.

http://www.vaxart.com

Latest From Vaxart, Inc.

Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital

Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs. 

Financing Innovation

Takeda Takes Alliance Route For Norovirus Vaccine

Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.

Deals Vaccines

Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors

Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.

Deal Watch Business Strategies

Altimmune Hit By Nasal COVID-19 Vaccine Failure, But Has A Plan B

Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.

Companies Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Other Names / Subsidiaries
    • Aviragen Therapeutics, Inc. (Anaconda Pharma SAS
    • Biota Holdings Limited
    • Biota Pharmaceuticals, Inc.
    • Nabi Biopharmaceuticals)
UsernamePublicRestriction

Register